The use of Biobrane® by burn units in the United Kingdom: A national study by Iain, Whitaker
b u rn s 3 3 ( 2 0 0 7 ) 1 0 1 5 – 1 0 2 0The use of BiobraneW by burn units in the United Kingdom:
A national study
I.S. Whitaker *, S. Worthington, S. Jivan, A. Phipps
The Yorkshire Regional Burns Unit, Pinderfield’s Hospital, Wakefield, United Kingdom
a r t i c l e i n f o
Article history:







a b s t r a c t
Biobrane1 is a biosynthetic wound dressing, first used byWoodruff in 1979, which hasmany
of the ideal properties of a dressing as outlined by Pruitt and Levine [Pruitt Jr BA, Levine NS.
Characteristics and uses of biologic dressings and skin substitutes. Arch Surg
1984;119(3):312–22]. It is becoming increasingly popular in the management of superficial
and moderate depth partial thickness burns and a range of other conditions. When used
appropriately, it has been shown to reduce pain levels, healing time, inpatient stay and
nursing requirements when compared to traditional dressings. We present the results of a
national study concerning the use of Biobrane1 in the United Kingdom, highlight variations
in practice, discuss the pertinent issues, make suitable recommendations and highlight the
versatility of Biobrane1 as a wound dressing.
# 2007 Published by Elsevier Ltd and ISBI.
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journal homepage: www.e lsev ier .com/ locate /burns1. Introduction
Biobrane1 is a biosynthetic wound dressing, first used by
Woodruff in 1979, which has many of the ideal properties of a
dressing as outlined by Pruitt and Levine [1]. It is composedof a
thin (6 mm) semi-permeable flexible silicone membrane
bonded to a layer of nylon fabric mesh (360 mm thick). The
nylon mesh is covered with a monomolecular layer of type I
collagen that provides a hydrophilic coating for fibrin ingrowth
and the initial adherence. Small pores are present in the
structure to allow for drainage of exudates and also provide
permeability to topical antibiotics [2]. More recently Biobrane
L1 has been introduced, with less adherent properties, aimed
for use on donor sites. Biobrane L1 contains a nylon fabric
woven frommonofilament threads (as opposed to tri-filament
threads seen in standard Biobrane1).
Biobrane1 is becoming increasingly popular worldwide in
the management of superficial and moderate depth partial
thickness burns. When used appropriately, it has been shown
to reduce pain levels, healing time, inpatient stay and nursing* Corresponding author at: 8 Avonlea Road, Sale, Cheshire M33 4HZ, U
E-mail address: iainwhitaker@fastmail.fm (I.S. Whitaker).
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doi:10.1016/j.burns.2006.11.017requirements when compared to traditional dressings [2–5].
To our knowledge there has been no study published
concerning the extent of use of biobrane or current practices
in the UK. We investigated such practices using a simple
questionnaire, and discuss the versatility of Biobrane1 as a
wound dressing.2. Method
A telephone questionnaire survey (see Table 1) of all regional
burns units in the United Kingdom was conducted between
October and November 2005 to investigate the current extent
of use of Biobrane, and to investigate current practice. The
names, addresses and phone numbers of the units were
obtained from the National Burns Bed bureau. The Burns unit
was contacted via hospital switchboard. Data was collected
from 32 units. Adult and Paediatric Burns Units were
considered separate units, even if they were on the same site
(n = 32). Accurate information was obtained from the Burnsnited Kingdom. Tel.: +44 161 9627563.
Table 1 – Questionnaire
1. Do you use Biobrane1 in your unit for the treatment of partial
thickness burns?
2. Do you use Biobrane1 to dress donor sites?
3. Do you use Biobrane1 for temporary coverage of excised full
thickness burns?
4. What age of patient would you consider using Biobrane1 on?
5. What burn location would you NOT consider using Biobrane1
on?
6. Do you use a general anaesthetic when applying Biobrane1?
7. When would you apply the Biobrane1?
8. What age of burn would you apply Biobrane1 to?
9. What agent do you use to prepare the site?
10. What method of attachment do you use?
11. Do you use antibiotic cover with Biobrane1?
12. What is the average inpatient stay?
13. What is your post-application of Biobrane1 regime?
14. Do you have a protocol for the use of Biobrane1?
Fig. 2 – Age of partial thickness burn injury thought
suitable for biobrane application.
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were included.Fig. 3 – Method of attachment to the burn/donor site.3. Results
The majority of burns units in the United Kingdom use
biobrane in the treatment of partial thickness burns (see
Fig. 1). Eight units (25%) used Biobrane1 to dress donor sites
and 12 (33%) used Biobrane1 to temporarily cover excised full
thickness burns before definitive grafting. All 22 units using
Biobrane1woulduse it on patients of any age. Twoadult burns
units would only use Biobrane1 on hand burns. Three
children’s burns units said they would not use Biobrane1
on facial burns. One unit would not use Biobrane1 on buttock
burns. Nineteen of the 22 units applied Biobrane1 in theatre
under a general anaesthetic. Three units applied Biobrane1 to
adult burns on the ward with analgesia. The timing of
application was dependent on the time of admission and on
theatre and staff availability, ideally before 9 p.m. on the day
of admission. In the majority of cases (13 units) this was
normally the following morning, after consultant review.
Therewere differences in the age of partial thickness burn that
units would consider dressing with biobrane (see Fig. 2). Nine
units used betadine to prepare the partial thickness burn site
before application of Biobrane1, three units used betadine
followed by saline and eight units used only saline. One unit
used betadine followed by chlorhexidine, and one unit usedFig. 1 – The extent of use of biobrane by burns units in the
United Kingdom.tap water and baby soap. Fourmainmethods were used in the
attachment of biobrane (see Fig. 3). Nine of the 22 units
routinely prescribed antibiotics at the time of biobrane
application. The average length of inpatient stay was
dependent on general condition of the patient, social situation
and size of the burn, but in general the majority of units sent
patients home within 24 h in well, uncomplicated patients,
with a handful of units keeping patients in for at least 48 h
(until the first dressing check).
Twelve units used a betadine soaked dressing over the
biobrane, and 10 units used plain gauze dressings. Six units
checked the biobrane every 24 h, and 16 units checked every
48 h. Dressing checks continued until the biobrane had
separated completely from the wound. If there was any
indication that the burn could have become infected,
harbouring pus or excessive ooze, the dressing was removed,
wound bed cleansed, and conventional dressings restarted.
Six units had protocols in place outlining the use of biobrane.4. Discussion
There is a great deal of literature available supporting the
successful use of Biobrane1 in the management of partial
thickness burns, particularly in paediatric patients [6–10]. This
is reflected with the majority of burns units in the United
Kingdom using biobrane to treat injuries of this nature.
Fig. 4 – Avoidance of stapling directly into the skin as much
as possible—stapling a ‘hem’ by attaching the BiobraneW
to itself.
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clinically superficial thickness, but not deep dermal wounds,
due to the increased chance of infection and significantly
delayed healing (see Fig. 1). Of the 10 units who did not use
Biobrane1, four used Mepitel1 or Aquacel Ag1, one used
Transcyte1, and the remaining five used jelonet. At least one
of the units using jelonet were interested in introducing the
use of Biobrane1.
All 22 units using Biobrane1 would consider using it on
patients of any age. Literature supporting its use in adult
patients is available [11,12], but its use in this population is less
widespread, particularly in smaller burn areas, with adults
tolerating traditional dressing changes much more readily.
Biobrane1 seems to be most useful in large burns [13] and
burns involving joints [14] and the hand [15,16]. It is of interest
that two adult burns units would only use Biobrane1 on hand
burns. Three children’s burns units said they would not use
Biobrane1 on facial burns. This approach seems sensible
considering the problems of mesh imprinting that have been
reported with the use of E-Z Derm dressing for facial burns
[17], with the use of Mepitel1 in similar situations [18] and the
appearance of punctuate scarring following the use of porous
Biobrane1 which has been recently reported in this journal
[19]. The use of non-porous dressings has been suggested in
certain circumstances to avoid this problem [20].
The use of Biobrane1 to manage donor sites has been
advocated by several authors, both in burned [21], and non-
burned patients [22–25]. In our study, eight units (25%) used
Biobrane1 to dress donor sites and 12 (33%) used Biobrane1 to
temporarily cover excised full thickness burns before defini-
tive grafting. Although alternative membranes are not used in
the treatment of superficial thickness burns in our experience,
xenograft of porcine origin and cadaveric allografts are often
used for the temporary coverage of large excised full thickness
burnswhere insufficient autograft is immediately available for
cropping or as a ‘sandwich graft’ in combination with 3:1
meshed allograft in an attempt to obtain early definitive
wound closure.
Nineteen of the 22 units applied Biobrane1 in theatre under
a general anaesthetic with three units applying Biobrane1 to
adult burns on the ward with analgesia. Children have a low
tolerance and high anticipation of pain, and exhibit poor co-
operation [26], so these findings are of no surprise.
The timing of application was dependent on the time of
admission and on theatre and staff availability, ideally before
9 p.m. on the day of admission. In the majority of cases (13
units) this was normally the following morning, after
consultant review.
It was previously advocated to apply Biobrane1within 24 h
of injury to reduce the risk of bacterial colonization [27], and
studies have shown that the application of Biobrane1 within
48 h of superficial burns provides for shorter hospitalizations
and faster healing times in children of all ages without
increased risk of infection [5]. There is no definitive evidence
however that precludes the application of Biobrane1 to older
burns, however due to the predilection of burn wounds to
undergo colonization early in their natural history, this
mitigates towards early application of occlusive dressings.
In our study there were differences in the age of partial
thickness burn that units would consider dressing withbiobrane (see Fig. 2), with 73%of units only applyingBiobrane1
to injuries occurring within 48 h, and the remaining 27%
placing it on older injuries.
Inourstudy, fourmainmethodswereusedintheattachment
of biobrane (see Fig. 3). The consensus conference convened in
1994inTexasgeneratedguidelines for theapplicationanduseof
Biobrane1 [28–30]. Recommendations included that Biobrane1
should be applied under tension and the edges secured with
adhesive tapes or steristrips. This method provides a straight-
forward but time consuming method of attachment. Wound
exudatesorbodyfluidssuchassweat,however,oftencausesthe
adhesive tapes to lose adherence resulting in loss of position
[31].Aviablealternativeistheuseofstaples.Theseproviderapid
andsecureattachment,withthedisadvantageofstapleremoval
causing further distress, particularly in the paediatric popula-
tion. The discomfort can be to some extent reduced by avoid
stapling directly into the skin as much as possible, and only
stapling a ‘hem’ by attaching the Biobrane1 to itself (see Fig. 4).
Obviously this is less important if anothergeneral anaesthetic is
planned for staple removal. Butyl-2-cyanoacrylate glue (His-
toacryl1) is our attachment of choice [31], by stretching the
Biobrane1 into position (Fig. 5) and dropping the glue onto
fenestrations in the silicon layer. The glue spreads out by
capillary action on the undersurface of themesh and results in
rapid stabilisation of the border. Thismethod allows fixation of
Biobrane1 toeitherdryormoist surfacesandallowsapplication
by a single operator. Unlike adhesive tape, where adverse
reactions have been reported [32,33], complications of Histoa-
cryl1attachmentarevirtuallynon-existentandtherehavebeen
no reports of clinically significanthistotoxicity [34–36]. In fact, it
has been reported that Histoacryl1 has a serendipitous
bacteriostatic activity against gram positive microorganisms
[37]. The chemical bond degenerates spontaneously over 7–10
days and separates spontaneously as underlying epidermis is
renewed.
Various modifications of application have been published
to overcome coverage of difficult areas, for example use of the
Biobrane1 glove to dress the foot [38] and the Biobrane1
‘jacket’ to dress the torso [27].
Fig. 5 – Stretching of BiobraneW over the wound bed,
applied under tension, with the dull side down, removing
wrinkles carefully.
Table 2 – Suggested guidelines
Appropriate conditions for use
Clean, well vascularised wound bed, devoid of eschar
Anaesthesia
General anaesthetic for children, oral analgesia/nitrous oxide for
adults
Agent to prepare site
Betadine followed by thorough cleansing with saline
Method of application (see Fig. 5)
‘Stretched’ over the wound bed, applied under tension, with the
dull side down, removing wrinkles carefully
Method of attachment
Tissue glue Histoacryl1/Dermabond1, or stapling separate sheets
to each other in a ‘hem’ (skin sparing)
Outer dressing
An absorptive dressing such as gauze
Follow up
Initial check at 24 h, then checks at 48 hourly until removal
In cases of infection—remove all biobrane, thorough cleansing
and use of traditional dressings
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timeof biobraneapplication. Burnsundoubtedly compromise
the immunestatusof any individual, by virtueof their barrier-
destroying properties, and pose a challenging problem
especially in very young children. Children are more prone
to bacterial super-infections, especially those patients below
the age of 5 years. These infections are largely due to
staphylococcus aureus (SA) and group A beta haemolytic
streptococcus (GABHS) [39,40]. It was suggested for example
that children with current or recent varicella zoster infection
should be a relative contraindication to the application of
Biobrane1 [9]. There has been a reluctance to use Biobrane1
by some individuals due to a perceived increase in infection
rates [41], with the literature reporting rates of between 5 and
6% [42]. Other views dispute the concern with regards to
infection rates, and believe Biobrane1 improves wound
healing with no increased infective risk [5]. On the plus side,
is the transparency of Biobrane1 allowing the immediate
identification of infection [10]. Biobrane1 is marketed on the
premise that thehighlypurifiedpeptides fromporcinedermal
collagen bonded to a nylon and silicone semi permeable
membrane, minimises bacterial proliferation by minimising
dead space. In the immunocompetent patient, at least one
randomised trial has shown that there were fewer infections
when Biobrane1was compared with 1% silver sulphadiazine
[6]. Clinical results show that Biobrane1 is effective in
controlling bacterial growth in wounds initially containing
<105 bacteria per gram of tissue when good adherence is
achieved [43].
If there is any indication that the burnhas become infected,
harbouring pus or excessive ooze, the dressing should be
removed, wound bed cleansed, and conventional dressings
restarted. We do not advocate the routine prescription of
antibiotics if the Biobrane1 is used to cover clean partial
thickness burns which are less than 48 h old.
It is of interest that only six units had protocols in the place
for the outlining the use of Biobrane1, further highlighting the
variations in practice.4.1. Our recommendations (see Table 2)
4.1.1. Religious and ethical issues
In a recent study of religious leaders [44], the vast majority
(77%) said that patients should be informed of the constituents
of the biological products and consent obtained. In the case of
the porcine content of Biobrane1, this could have conse-
quences for consenting particularly the Muslim community.
Ignoring religious sensitivities and neglecting consent in the
usage of Biobrane1 could have serious implications including
litigation. It is very worrying that none of the heathcare
professionals questioned in the same survey knew the
constituents of biological dressings correctly [44].
4.1.2. Adverse effects of Biobrane1
Adverse affects following the use of Biobrane1 are uncom-
mon, however surgeons should be aware of the possibility of
contact dermatitis [45]. In the first description of such a case,
the patient developed a bullous skin reaction directly related
to a second exposure to Biobrane1, 18 days after the initial
application, and the bullous reaction developedwithin 48 hof
repeat exposure. Sensitivity was confirmed by patch testing.
Hypersensitivity to Biobrane1 was reported the following
year [46]. Punctate scarring coincidingwith theposition of the
pores in the Biobrane1 dressing has recently been described
in this journal in two cases of paediatric partial thickness
burns [1].
4.1.3. Alternative uses of Biobrane1 in reconstructive and
burn surgery units
Of interest to the plastic and reconstructive surgeon is the use
of Biobrane1 in axillary reconstruction following surgical
excision for hydradenitis suppurativa [47]. This method
provided a single stage procedure, with no donor site
morbidity and exhibited the ability to use Biobrane1 in
colonised tissues. The limitations included a longer healing
time and increased cost of dressing. Biobrane1 has also been
successfully used following laser resurfacing of the face
b u rn s 3 3 ( 2 0 0 7 ) 1 0 1 5 – 1 0 2 0 1019[48,49]. Studies showed that Biobrane1 adhered well to the
skin post procedure, was well tolerated, minimised pain and
drainage, decreased erythema, reduced healing time and
simplified nursing care. Similarly, Biobrane1 has been used as
a dressing followingmechanical dermabrasion [48,50,51]. This
study showed Biobrane1 reduced erythema and healing time
by up to 50% when compared to air-exposed wounds. It was
also associated with a lower incidence of milia formation. The
use of Biobrane1 has been reported in the successful
treatment of serious skin conditions such as toxic epidermal
necrolysis [52–55] and paraneoplastic pemphigus [56]. Bio-
brane1 was applied to the extensive areas of erosion to assist
in pain management and to provide a temporary barrier
function. Standard dressings such as silver sulfadiazine were
too messy and caused discomfort with frequent changing.
The treatment of serious skin conditions such as TEN and
pemphigus with Biobrane1 is an area that warrants further
evaluation with large randomised controlled trials as it may
contribute to the overall treatment and comfort cares of these
patients.
Chronicwounds such as large venous ulcers have also been
successfully managed using Biobrane1 [57]. Several case
reports concerning the use of Biobrane1 are present in
contemporary literature. The skin substitute has been used
in the treatment of a life threatening oesophageal fistula by
covering an expandible metallic stent [58] and in the manage-
ment of subcutaneous colostomy perforation [59] where the
Biobrane1 served as a temporary dressing, providing good
stability, and supported the application of a stoma appliance.
Biobrane1 has also been used in the successful management
of a sternotomy wound which could not be closed immedi-
ately due to massive intra-operative oedema formation [60].
To protect the mediastinum from infection, Biobrane1 was
applied to the surgical wound and amoist gauze dressing over
it. When the dressing was removed 4 days later, the wound
was pink, granulating, free from infection, and suitable for
closure.
This manuscript highlights the variations in practice with
regards to the use of Biobrane1 in the United Kingdom and
discusses relevant issues. We believe that Biobrane1 is a
highly versatile toolwhich should be in the armamentariumof
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